

Use of Anti TNF- α Therapy in Systemic Vasculitis

Talal Al-Mteri¹, Fatma Al-shaiki², Shahd Hafiz¹, Rabab Taha³, Omar Fathaddien⁴ and Hani Almoallim^{1,3,5*}

¹Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia

²Department of Medicine, King Fahad General Hospital, Jeddah, Saudi Arabia

³Department of Medicine, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia

⁴Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

⁵Alzaidi Chair of Research in Rheumatic Diseases, Faculty of Medicine, Umm-Al Qura University, Makkah, Saudi Arabia

*Corresponding author: Hani Almoallim, Alzaidi Chair of Research in Rheumatic Diseases, Faculty of Medicine, Umm-Al Qura University, Makkah, Saudi Arabia, E-mail: hmmoallim@uqu.edu.sa

Received date: Nov 08, 2016; Accepted date: Jan 01, 2017; Published date: Feb 15, 2017

Copyright: © 2017 Al-Mteri T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

There are several vasculitic disorders still labeled as difficult-to-treat cases. Effective treatment for those patients is warranted to reduce the mortality and morbidity that resulting from these disorders. An extensive review for the literatures that addressed using of anti TNF-alpha in several vasculitic disorders was conducted. Use of anti TNF-alpha agents is a promising modality in several vasculitic disorders. Despite lacking well-conducted randomized controlled trials, more open-label studies are required to examine in-depth the safety and efficacy of those agents.

Keywords: Vasculitic disorders; Systemic vasculitis; TNF α ; Macrophages

Background

There are several vasculitic disorders still labeled as difficult-to-treat conditions due to its rarity and complexity at the time of presentation [1]. The need for effective treatment for vasculitis is demanding since it carries a high incidence of morbidity and mortality either as a long term consequence of the disease itself or from the therapeutic interventions [1]. However, the available studies to provide evidence of therapies to practicing clinicians are mostly based on non-randomized controlled trials. Conducting a well-controlled randomized clinical trial is difficult due to multiple limitations; for example, failure to establish a measurable endpoint in vasculitic disorders leads to different endpoints, making it difficult to obtain evidence from these trials [2,3]. Having a statistical power by large number of patients is another limitation due to its rarity [2,3]. Tumor necrosis factor is a pro inflammatory cytokine primarily by ipopolysaccharide stimulated macrophages and monocytes [4]. TNF- α plays a crucial role in process of inflammation via several ways which include adhesion molecule expression, pro inflammatory cytokine release and inhibition of regulatory T cells. TNF- α is increasingly considered as a central player in pathophysiology of systemic vasculitis, a targeting therapy to TNF α is the current trend to treat systemic vasculitis [5].

Introduction

The available anti TNF- α agents are Infliximab, Adalimumab, Etanercept, Certolizumab pegol and Golimumab. Infliximab is a chimeric monoclonal antibody composed of a murine variable region attached to human Fc (constant) portion of IgGk. Adalimumab is a fully humanized monoclonal antibody, dosed every second week as a subcutaneous injection. While etanercept is a fusion protein produced by recombinant DNA. It fuses the TNF receptor to the constant end of the IgG1 antibody. On the other hand, Certolizumab pegol is a

humanized antigen binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol [6]. Finally, Golimumab is a human immunoglobulin G1 kappa (IgG1) monoclonal antibody specific for human tumor necrosis factor (TNF; TNF α) [7].

Concerns were present toward increased risk for infections, malignancy and cardiovascular disease with the use of anti TNF- α . However, one study demonstrates that among 16,000 patients treated with anti TNF- α for rheumatoid arthritis there was no increase of the serious bacterial infections in comparison to patients treated with methotrexate (MTX) [8]. Overall, the use of anti TNF α is associated with an increased risk of infections. Caution should be addressed while using these drugs in daily clinical practice. Regarding the risk of malignancy; recent analysis from Lombardy Rheumatology Network (LORHEN) registry addressed no increase in the malignancy risk in comparison to the general population, however the risk of hematological malignancy especially lymphoma was significantly increased in people who are older than 65 years [9].

In comparison to conventional DMARDs; anti TNF- α agents do not increase the risk for cardiovascular events [10]. Table 1 summarizes the all available anti TNF- α agents used in treatment of vasculitis.

In this article, we have conducted extensive review of different publications that addressed the use of anti TNF- α agents in vasculitis as shown in (Figure 1). Aiming to deliver a comprehensive overview of the best and the latest evidence in this field.

Takayasu Arteritis

Takayasu arteritis (TA) is an idiopathic panarteritis affects the large and medium vessels especially the aorta and its branches, with onset of age before 30. It is characterized by granulomatous inflammation in the involved site [11]. TNF- α is an important cytokine for granuloma formation. Activated T cells, natural killer cells, γ/δ cells and macrophages are also important pathophysiological principles of TA's

development [11]. The mainstay therapy consists of glucocorticoid (GC) and methotrexate (MTX [12]. Only 40- 60% of patients with TA achieve remission on conventional therapy [12]. Thus, the need of new modality of treatment is warranted to achieve remission in the remaining patients. The clinical benefit of anti TNF- α in TA has been demonstrated via several case reports and series. One case series observed 15 patients with resistant TA [13], in all patients who received GC the relapses were observed while the dose was tapered down. In this study, patients were divided into two groups, 7 patients received etanercept, the remaining 8 patients were started on infliximab. Out of these 15 patients, 93% showed significant improvement, while 67% experienced GC-free remission for 3 years after follow-up. Another case series described the effect of anti TNF- α on TA [14]. Five patients with TA failed to achieve remission on conventional therapy. Infliximab was initiated with MTX as a concomitant immunosuppressive agent in 4 cases, one case was on AZA. The follow-up duration was ranging from 3 to 72 months. It showed only one relapsed case. The other four cases showed successful tapering of GC dose with no relapse upon follow-up. Additionally, a literature review of 79 cases with TA showed significant response on infliximab and etanercept [14]. Global improvement was observed in 90%, complete remission in 37% and partial remission in 53%, patients who do not respond to anti TNF- α therapy were only 9%. One study evaluated 8 patients with refractory TA; two of them were refractory to infliximab therapy and 3 patients did not achieve remission on GC and MTX. However, all patients received tocilizumab (interleukin-6 receptor antagonist) therapy and the follow-up showed 7 out of 8 patients achieved remission. This data shows an interesting finding that tocilizumab can be a potential therapy for refractory TA to anti-TNF- α therapy [15]. Case series of 10 patients showed a sustainable remission on tocilizumab therapy in 60%, the other 40% failed to satisfy the criteria of sustainable remission, requiring either clinical or biochemical criteria of remission [16]. Interestingly, out of 6 patients who achieve sustainable remission on tocilizumab underwent follow-up after discontinuation, only 2 patients maintain their complete remission on post-tocilizumab follow-up period (3-14) months [16]. These finding can raise the concerns regarding the effectiveness of tocilizumab as a steroid-sparing agent.

In conclusion, anti TNF- α can be a potential therapy for patients with steroid-resistant TA. However, relapsed cases on anti TNF- α agents were reported as well. Tocilizumab can be a potential option in these cases, although there are reports of relapses after holding the tocilizumab. Overall, further placebo-controlled studies should be conducted to improve the current quality of evidence available for practicing clinicians. Table 1 shows a summary of studies that addressed the use of anti TNF- in patients with TA [17-21].




Figure1: Summary Of Anti-TNF α Agents In Systemic Vasculitis

Out of these 15 patients, 93% showed significant improvement, while 67% experienced GC-free remission for 3 years after follow-up. Another case series described the effect of anti TNF- α on TA [14]. Additionally, a literature review of 79 cases with TA showed a significant response to infliximab and etanercept (14). Global improvement was observed in 90%, complete remission in 37% and partial remission in 53%, patients who do not respond to anti TNF- α therapy were only 9%. One study evaluated eight patients with refractory TA; two of them were refractory to infliximab therapy, and three patients did not achieve remission on GC and MTX. However, all patients received tocilizumab (interleukin-6 receptor antagonist) therapy, and the follow-up showed 7 out of 8 patients achieved remission. This data shows an interesting finding that Tocilizumab can be a potential therapy for refractory TA to anti-TNF- α therapy [15]. Case series of 10 patients showed a sustainable remission on tocilizumab therapy in 60%, the other 40% failed to satisfy the criteria of sustainable remission, requiring either clinical or biochemical criterion of remission [16].

Agent	Mechanism of action	Side effects	Pregnancy considerations
Infliximab	Binding antibody (chimeric IgG1). Thereby interfering with endogenous TNF- α	Headache (18%), Increased serum ALT, Increased ANA titer and infections.	Category B
Etanercept	Recombinant DNA-derived protein composed of tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.	Headache (17%), Skin rash, abdominal pain and Infections	Category B
Adalimumab	recombinant DNA-derived human immunoglobulin G1 (IgG1) monoclonal antibody specific for human tumor	Hepatitis B infection reactivation, Exacerbation of demyelinating diseases,	Category C

	necrosis factor (TNF- α)	Pancytopenia, Infection	
Certolizumab	Certolizumabpegol binds to and selectively neutralizes human TNF-alpha activity.	Aplastic anemia, thrombocytopenia, Antibodies to Certolizumab.	Category B
Golimumab	monoclonal antibody that binds to human tumor necrosis factor alpha (TNF α)	Positive ANA titer, Leukopenia, High serum ALT,	Category B

Table 1: Summary of different agents under Anti TNF α class.

Five patients with TA failed to achieve remission on conventional therapy. Infliximab was initiated with MTX as a concomitant immunosuppressive agent in 4 cases, one case was on AZA. The follow-up duration was ranging from 3 to 72 months. It showed only one relapsed case. The other four cases showed successful tapering of GC dose with no relapse upon follow-up. Additionally, a literature review of 79 cases with TA showed significant response on infliximab and etanercept [14]. Global improvement was observed in 90%, complete remission in 37% and partial remission in 53%, patients who do not respond to anti TNF- α therapy were only 9%. One study evaluated 8 patients with refractory TA; two of them were refractory to infliximab therapy and 3 patients did not achieve remission on GC and MTX. However, all patients received tocilizumab (interleukin-6 receptor antagonist) therapy and the follow-up showed 7 out of 8 patients achieved remission. This data shows an interesting finding that Tocilizumab can be a potential therapy for refractory TA to anti-

TNF- α therapy [15]. Case series of 10 patients showed a sustainable remission on tocilizumab therapy in 60%, the other 40% failed to satisfy the criteria of sustainable remission, requiring either clinical or biochemical criteria of remission [16]. Interestingly, out of 6 patients who achieve sustainable remission on Tocilizumab underwent follow-up after discontinuation, only 2 patients maintain their complete remission on post-tocilizumab follow-up period 3-14 months [16]. These finding can raise the concerns regarding the effectiveness of Tocilizumab as a steroid-sparing agent.

Giant Cell Arteritis

Giant cell arteritis (GCA) is a most common form [22,23] as a multisystem granulomatous vasculitis predominantly targets large and medium sized arteries [24,25]. Classical disease therapy relies on a high dose of GC administration once the clinical finding is suggestive of the disease [25,26]. Relapse is common in 60-70% of patients thus, other therapeutic modalities are required [23,27,28]. A meta-analysis in 2014 [29], included five studies about anti TNF alpha agents in GCA. It failed to prove any beneficial effect. Table 3 shows a summary of studies that addressed the use of anti TNF- α agents in patients with GCA [30-32].

Behçet's Disease

Behçet's Disease (BD) is an inflammatory disorder characterized by recurrent oral aphthous ulcer and systemic manifestations: genital ulcer, skin lesion and neurological manifestations [33]. The ability of BD to involve more than one type of vessels makes it unique and remarkable vasculitic disease.

Author	Study type	Date	Methodology	Used agent	Outcomes
Vinickia et al. [17]	Retrospective analysis from medical records	2016	Ten patients were identified, who fulfill the ACR diagnostic criteria for GCA, TA	Infliximab, Etanercept and Tocilizumab	Sustained remission was achieved in all cases during follow-up (mean follow-up 59.6 \pm 27.2 months) with decrease in Glucocorticoid dose in 70%. One patient discontinued Infliximab due to recurrent infections - One patient with neutropenia
Abisor et al. [19]	Retrospective analysis and review of the literature	2013	Five patients multicentric cases, another 39 cases from review of the literature	Tocilizumab	Remission in 93% of the cases, 78% at 6 months and 75% at the time of last visit (11 months). Mild Nutropenia
Alberto Canas et al. [15]	Retrospective analysis of 8 patients	2014	Eight patients who treated with tocilizumab for median duration of 18 months were reviewed from the records between 2010 and 2013	Tocilizumab	. All the eight patients showed global improvement. Three patients have needed adding immunosuppressive after TCZ therapy
Nakaoka et al. [20]	Prospective study for four patients	2013	From June 2008 till February 2011. Four patients were identified as Glucocorticoid resistant Takayasu arteritis started on TCZ therapy	Tocilizumab	Significant reduction in the thickening of vessel walls in 2 patients. All the patients attained outstanding reductions in the prednisolone doses

Comarmond [14]	Retrospective analysis and review of the literature	2012	84 patients (5 personal cases and 79 patients from the literature) with refractory Takayasu arteritis treated with anti TNF- α	Infliximab, Etanercept	Thirty one patients achieved complete remission, 45 patients labeled as partial responders and eight were non-responder. -8 patients with infections, 4 with hypersensitivity, 1 immune reaction, 1 breast cancer, 1 Nausea and diarrhea, 1 cardiac failure
Goel et al. [16]	Retrospective analysis	2013	Medical records for 10 patients Takayasu arteritis who received Tocilizumab therapy were reviewed and analyzed.	TCZ	7 patients reached sustainable remission, 3 relapsed patients. Remission was not maintained after discontinuation of TCZ. -One patient with transient skin rash, transient transaminitis,
Nunes et al. [21]	Retrospective analysis	2010	Review medical files of 15 patients who attend Rheumatology clinic for Takayasu arteritis between July, 2007- July, 2008	IFX	Out of 15 patients only 3 received TNF blocker agents due to steroid-Resistant disease. Shows a complete remission upon follow up - No documented adverse effects

Table 2: Summary of the studies that investigate using of anti TNF- α agents in Takaysu arteritis.

The current therapeutic modalities for BD came from case reports and case series, with few follow-up studies. Currently, for minor disease manifestations; a regimen consists of colchicine initially and GC for patients who do not respond well for colchicine [34,35]. For major disease manifestations; typical regimen is high dose of GC (1 mg/Kg/day) not exceeding 80 mg/day. The effect of anti TNF- α in BD

has been investigated thoroughly, the beneficial effect of infliximab, adalimumab, and etanercept was reported [36,37]. In a multicenter observational study including 164 patients with BD with uveitis received infliximab for more than a year, infliximab was found reducing the number of ocular attacks per year [38].

Author	Study Type	Publishing Date	Materials and Methods	Used Agents and Dose	Results
Hoffman et.al [30]	Randomized controlled trial	2007	44 GCA patients, 28 patients received infliximab and 16 patients received placebo all together with corticosteroid	5 mg/kg of Infliximab	At week 22, relapse rate was 43% in Infliximab group and 50% in Placebo group Tapering steroid without relapse was 61% in Infliximab group compared with 75% in placebo group. Infection incidence in Infliximab group was 71% compared to 56% with placebo group.
Martinez et al. [31]	Randomized controlled trial	2008	17 GCA patients, for 12 months. Eight patients received etanercept and 9 received placebo all in addition to corticosteroids.	25 mg Etanercept, twice/week	Controlling disease without steroid after 1 year was achieved in 50% of patients on Etanercept and in 22.2% of placebo patients. Significant decrease in steroid dose in Etanercept. Similar reported Side effects in both groups.
Seror et al, [32]	Randomized controlled trial	2013	70 GCA patients. 34 received prednisolone plus adalimumab and 36 received prednisolone plus placebo.	40 mg subcutaneous Adalimumab. For 10 weeks	Remission was achieved at week 26 in 20 patients in Adalimumab group and in 18 in the placebo. After steroid tapering both groups were similar in relapse free patients.

					Serious side effects were reported in 5 patients on adalimumab group and 17 on placebo
--	--	--	--	--	--

Table 3: Summary of the studies that investigate using of anti TNF- α agents in Giant cell arteritis.

Surprisingly, relapsed uveitis has been reported in 60% of the patients on infliximab therapy especially in the first year, and symptoms were controlled by increasing the topical GC dose and shortening the interval of infliximab therapy. In retrospective analyses of 28 patients with moderate to severe intestinal BD [39], patients were followed and achieved a clinical response reaching 75%. (Median duration of follow-up is 30 months). In a double blind study on BD [40], more patients remained free of oral lesions after etanercept therapy (45% versus 5% in control group), in terms of nodular skin lesion (85% versus 25%) were observed. Benefit of adalimumab has been reported in one case series [41]. However, some patients who

failed infliximab therapy might achieve remission on adalimumab, 17 of 69 patients investigated for this purpose [42], out of those 17 patients only 12 achieved improvement on adalimumab therapy. Anti TNF- α can be a valuable modality inducing and maintaining remissions with steroid and immunosuppressive sparing effect for patients with severe BD who failed to achieve remission on conventional therapy. High-quality level of evidence is warranted to assist the practicing rheumatologist in toward difficult-to-treat cases of BD. Table 4 shows a summary of studies that addressed the use of anti TNF- α agents in patients with BD [43].

Author	Study type	Date	Methodology	Used agent	Outcomes
Takeuchi et al. [38]	Prospective analysis	2014	A total of 164 consecutive patients with BD treated with Infliximab for more than 1 year were studied. The mean treatment duration was 32.9 \pm 14.4 months.	Infliximab	60% relapse in uveitis cases after first year, Control was made in 90% of the cases later on by increasing topical steroid and infliximab doses.
Lee et al. [39]	retrospective non-controlled review of medical records	2013	28 patients with intestinal BD who received at least 1 dose of Infliximab. Response rates of Infliximab at 2, 4, 30, and 54 weeks for each patient were investigated	Infliximab	The clinical response rates at 2, 4, 30, and 54 weeks were 75%, 64.3%, 50%, and 39.1%, respectively.
Cantini et al. [43]	Prospective analysis	2012	Single center, prospective, 6-year duration, follow-up study on 50 consecutive patients	Infliximab	A complete response was recorded in 34/50 (68%) patients and partial response in 11/50 (22%). Five patients were nonresponders No serious side effects
Melikoglu et al. [40]	Double blind, placebo controlled study.	2005	Forty male patients with BD, were randomized (20 patients to each study arm) to receive either Etanercept 25 mg twice a week or placebo for 4 weeks	Etanercept	More patients remained free of oral ulcers (45% versus 5%). -More patients remained free of nodular skin lesions (85% versus 25%).
Bawazeer et al. [41]	Retrospective review of records.	2010	Twenty-one eyes of 11 male patients with ocular Behçet disease received Adalimumab therapy.	Adalimumab	Ten out of 11 patients showed complete resolution of inflammation by 4 weeks. The dosage of steroid and immunosuppressive drugs were reduced, then stopped in 3 and 6 patients respectively.
Olivieri et al. [34]	prospective, longitudinal and observational study	2011	Data were collected on every patient with BD beginning anti-TNF therapy in the last 8 years. Patients should be switched to Adalimumab after failing or not tolerating Infliximab.	Adalimumab	Initially 69 treated with Infliximab, lack of response or infusion reaction necessitated administration of Adalimumab, out of those 17, nine patients showed sustained remission and 3 patients with good response.

Table 4: Summary of the studies that investigate using of anti TNF- α agents in Behçet's disease.

Cryoglobulinemic Vasculitis

It is a systemic inflammatory condition that involve small to medium sized vessel vasculitis caused by cryoglobulin contained

immune complex deposition [44]. Conventional treatment of this vasculitis started by treatment of underlying cause as in hepatitis C virus (HCV)-associated cryoglobulinemic vasculitis [45]. Rituximab (RTX) (Anti-CD20) showed benefit in life threatening conditions [46],

while CYC reserved for refractory cases to antiviral or RTX. Anti- TNF agents have a promising effect. Infliximab showed positive effect in one reported case that failed to achieve remission on conventional therapy [47].

Author	Study Type	Publishing Date	Materials and Methods	Used Agents and Dose	Results
Bartolucci et al. [48]	Prospective study	2002	Ten patients with different vasculitis, one case had cryoglobulinemic vasculitis, with active disease or new flare despite conventional therapy.	Infliximab 5 mg/kg at day1, 14, 42, and Q8 weekly. Evaluated by BVAS score.	Symptomatic improvement. No side effect.
Koukoulaki et al. [49]	Case report	2005	Young women known case of hepatitis C negative cryoglobulinemic vasculitis on conventional therapy developed intestinal vasculitis and significant GI bleeding	Single dose of Infliximab 5 mg/kg	Stabilization of patient bleeding and HB level and discharge home.

Table 5: Summary of the studies that investigate using of anti TNF- α in cryoglobulinemic vasculitis.

Single dose of infliximab 5mg/kg results in complete resolution of the symptoms; followed by uneventful clinical course for one patient complaining of cryoglobulinemic vasculitis with gastrointestinal bleeding. Table 5 shows a summary of studies that addressed the use of anti TNF- α agents in patients with cryoglobulinemic vasculitis [48,49].

Kawasaki Disease

Kawasaki disease (KD) is a form of medium sized vasculitis most commonly affects coronary arteries. In children KD is the second most common vasculitis [50]. Marked elevation of serum TNF- α found in sera of KD patients [51].

Acute KD management strategy involves administration of 2 g/kg as a single infused intravenous immunoglobulin (IVIG) with high dose aspirin. Aspirin can be continued as a low dose until echocardiograms is normal [52]. Almost 15-20% of patients failed to respond to initial IVIG [52]. In those refractory KD patients, anti TNF α agents have been investigated [53]. Several retrospective studies, case series, and case reports addressed infliximab effectiveness in refractory KD.

From 2004-2006 [54], 24 patients with refractory KD received either infliximab or a second dose of IVIG. Each group contained 12 patients. Symptoms subsided in 11 patients on infliximab group versus in 8 who were on IVIG. Two out of 4 who did not respond were in IVIG group, had responded to infliximab later on. Another 2 studies addressed the effect of adding infliximab to the standard therapy. In 2014 [55] a phase 3, randomised, double-blind, placebo-controlled trial was conducted on 196 patients to assess the benefit adding of infliximab to the conventional therapy. The results came to show infliximab didn't reduce the disease resistance rate.

Etanercept is an under-studied anti TNF- α agent for refractory KD. A prospective open label trial of 17 patients with KD [56], all enrolled patients received IVIG plus aspirin, etanercept was administrated immediately after IVIG infusion. No complications or side effects have occurred in all 15 patients. Table 6 shows a summary of studies that addressed the use of anti TNF- α agents in patients with Kawasaki disease [57-63].

Author	Study type	Date	Materials and Methods	Used Agent and dose	Results
Burns et al. [74]	Retrospective study	2005	16 US patients resisted initial IVIG	Infliximab 5 mg/kg	81.25% of patients (13) responded well to single infusion of Infliximab. No reported side effects. CRP declined in 10 patients after 48 hours on infliximab infusion
Burns et al. [58]	A multi centers Randomized Controlled Trial.	2005	24 refractory KD cases failed 1st IVIG. Either Infliximab or a 2nd dose of IVIG was given. Each group contained 12 patients.	Infliximab 5 mg/kg	Symptoms subsided in 11 Patients on Infliximab and 8 on IVIG. Two out of 4 who did not respond to IVIG had responded to infliximab. Side effects related to disease course developed in 18 patients. Transient hepatomegaly with spontaneous resolution reported in 10 patients (couldn't be ruled out before treatment) No significant differences between the 2 drugs.
Song et al. [59]	Retrospective study	2004- 2008	16 KD patients in Korea	5-6.6 mg/kg of Infliximab	13 cases resolve completely. 2 cases achieved permanent resolution of arthritis

			At least 2 doses of IVIG were given with or without steroid		14 patients had decreased CRP after Infliximab Coronary artery lesions found in 15 of 16 before Infliximab, dilatation was stopped or delayed after Infliximab. No infusion reactions or complications were noted in all patients 1 case only developed acute hepatitis during treatment and calculus cholecystitis 4 months later
Son et al. [60]	retrospective study	2011	106 refractory KD failed to respond to 1st IVIG dose. 20 patients received Infliximab compared to 86 patients received 2nd IVIG.	Infliximab 5 mg/ kg	Infliximab patients had fewer days of fever and shorter hospital stay. Both groups were similar in coronary artery size after 6 weeks, also in adverse effects
Mori et al. [57]	open label case series	2012	20 patients received Infliximab after failure of IVIG therapy	Infliximab, 5 mg/kg	Rapid symptomatic improvement in 18 patients, subsided inflammatory mediators. And Mildly dilated coronary artery returns to normal after 1 month of Infliximab. No reported side effects or complications
Burns et al. [61]	randomized clinical trial	2013	7 KD patients received IVIG and 7 received IVIG in addition to infliximab	Infliximab (5 mg/kg)	no adverse effect on immunological cells associated with Infliximab treatment
Tremoulet et al. [62]	Phase 3 randomized, double-blind, placebo-controlled trial	2014	98 patients received Infliximab plus standard treatment compared to 98 patients received placebo plus standard therapy.	Infliximab 5 mg /kg	Infliximab group had better outcomes, no infusion reaction to IVIG compared with 13.4% in Placebo group. Resistance to IVIG treatment in KD did not reduce after Infliximab addition
Youn et al. [63]	Randomized controlled trial	2016	43 KD patients resisted 1st dose of IVIG. 32 KD received second dose of IVIG compared to 11 KD who received infliximab	Infliximab 5 mg /kg	Better response was noticed in Infliximab group in term of shortening the duration of fever and hospitalization, 90.9% and 65.6% respectively Similar adverse events and coronary artery outcomes

Table 6: Summary of the studies that investigate using of anti TNF- α agents in Kawasaki disease.

Polyarteritis Nodosa

Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects small and medium-sized arteries [64]. The treatment and the prognosis are highly variable depending on the extent of the disease if it is systematic or localized to the skin. Despite aggressive medical management with GC and CYC, many patients develop aggressive disease refractory to all available modalities with high

incidence of mortality reaching up 22.4% within five years from the disease onset [65]. Several reported cases showed remission after failing of conventional therapy [65-67]. The selected cases cover a broad spectrum of clinical presentation representing different age groups. In each case, patients were treated with one or a combination of GC and immunosuppressant with little or no response to treatment.

Author	Study Type	Publishing Date	Material and Methods	Used Agent and Dose	Outcomes
Lara et al.	Case report	2013	Young male with relapsed cutaneous polyarteritis nodosa after different trials of treatment.	Etanercept 50 mg/sc weekly	Complete remission achieved after three month. Patient has been followed for 7 years with absolute remission
Maurizio et al.	Case report	2014	Young male with systemic PAN relapsed on corticosteroid, high doses of CYC and trials of IVIG.	Etanarecept 50 mg/sc	Clinical response after 2 months.

				weekly	Complete remission after 2 years
Jeffrey et al.	Case report	2005	Young male with refractory systemic PAN for 9 years despite treatment with corticosteroid, and CYC.	Etanercept 50 mg/SC weekly	Remission
Al-Bishri et al.	Case report	2005	Young Female diagnosed as a severe (PAN) with visceral involvement. She received high doses of corticosteroid and CYC with no response.	Infliximab 3mg/kg at 0,2,and 6 weeks then every 8 weeks	Remission
Takeshi et al.	Case report	2012	Sixty years old female with PAN with hep B Received intensive treatment of Prednisolone, CYC, AZA, Tacrolimus IVIG & plasma exchange	Etanercept 25 mg/kg sc weekly lamivudine 100 mg/day	Remission With no reactivation of hepatitis B
Watanabe et al.	Case report	2016	3-year-old- male, PAN with vertebral artery vasculitis, treated with methylprednisolone and CYC.	Tocilizumab 4 mg/kg q 4week	Remission was achieved within 7 month.
Seri et al.	Case report	2015	59 male patients with PAN treatment failed on steroid and CYC	RTX 375 mg/m ² IV infusion Weekly	Remissions
Almoallim et al.	Case report	2009	18 years old male with PAN and gangrenous fingers, was in refractory to different treatment with prednisolone, MTX, MMF and CYC.	Adalimumab 40 mg subcutaneously every two weeks. Maintenance on MMF	Remission after the fourth injection.

Table 7: Summary of the studies that investigate using of anti TNF- α agents in Polyarteritis nodosa.

Few cases were treated with etanercept [65-67], one with infliximab [68], tocilizumab [69], adalimumab [70] and lastly, a case treated with rituximab [71]. All cases showed a good response to treatment with achieved remission upon clinical and biochemical basis without serious side effects. Although we found no prospective studies or large trials addresses the role of anti-TNF in inducing or maintaining remission in patients with PAN, there are several case reports that suggest the benefits of anti-TNF-alpha in severe and refractory cases. More studies are required to determine the safety and efficacy of anti-TNF treatment in PAN. Table 7 shows a summary of studies that addressed the use of anti TNF- α agents in patients with PAN.

Conclusion

Use of anti TNF- α agents is a promising modality in the field of vasculitis management. Despite lacking of well-conducted randomized controlled trials in several vasculitic disorders, anti TNF- α agents remain an optional therapy for difficult-to-treat cases. It has to be noted that anti-TNF alpha agents showed no beneficial effects in ANCA-associated vasculitis (AAV) [72]. In fact, these agents can induce autoimmune syndromes like vasculitis e.g. Henoch-schönlein purpura [73]. Collectively, we encourage clinicians, in the field of taking care of vasculitis patients, to raise their collaboration level; with the aim to reach a better evidence-based clinical practice.

References

- Roane DW, Griger DR (1999) An approach to diagnosis and initial management of systemic vasculitis. *Am Fam Physician* 60: 1421-1430.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, et al. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 363: 221-232.
- Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al. (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 363: 211-20.
- Vassalli P (1992) The pathophysiology of tumor necrosis factors. *Annu Rev Immunol* 10: 411-452.
- Aries PM, Lamprecht P, Gross WL (2007) Biological therapies: new treatment options for ANCA-associated vasculitis? *Expert Opin Biol Ther* 7: 521-33.
- Goel N, Stephens S (2010) Certolizumab pegol. *mAbs* 2: 137-47.
- Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, et al. (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. *Arthritis Res Ther* 17:14
- Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, et al. (2007) Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. *Arthritis Rheum* 56: 1754-64.
- Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, et al. (2010) Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. *Autoimmun Rev* 9: 175-80.
- Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, et al. (2009) European biologicals registers: methodology, selected results and perspectives. *Annals of the rheumatic diseases*.
- Dabague J, Reyes PA (1996) Takayasu arteritis in Mexico: a 38-year clinical perspective through literature review. *Int J Cardiol* 54: S87-S93.
- Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, et al. (1994) Takayasu arteritis. *Ann Intern Med* 120: 919-929.

13. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. *Arthritis Rheum* 50: 2296-304.
14. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, et al. (2012) Anti TNF- α in refractory Takayasu's arteritis: cases series and review of the literature. *Autoimmun Rev* 11: 678-684.
15. Cañas CA, Cañas F, Izquierdo JH, Echeverri A-F, Mejía M, et al. (2014) Efficacy and Safety of Anti-Interleukin 6 Receptor Monoclonal Antibody (Tocilizumab) in Colombian Patients With Takayasu Arteritis. *JCR: J Clin Rheumatol* 20: 125-9.
16. Goel R, Danda D, Kumar S, Joseph G (2013) Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. *Int J Rheumatic Dis* 16: 754-61.
17. Vinicki JP, García-Vicuña R, Arredondo M, López-Bote JP, García-Vadillo JA, et al. (2016) Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases. *Reumatología Clínica*.
18. de Kussmaul A, Maier R (1866) Über eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. *Dtsch Arch Klin Med* 1: 484-517.
19. Abisror N, Mekinian A, Lavigne C, Vandenhende M-A, Soussan M, et al. (2013) Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. *Autoimmun Rev* 12: 1143-9.
20. Nakaoka Y, Higuchi K, Arita Y, Otsuki M, Yamamoto K, et al. (2013) Tocilizumab for the treatment of patients with refractory Takayasu arteritis. *Int Heart J* 54: 405-11.
21. Nunes G, Neves FS, Melo FM, de Castro GR, Zimmermann AF, et al. (2010) Takayasu arteritis: anti-TNF therapy in a Brazilian setting. *Rev Bras Reumatol* 50: 291-298.
22. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, et al. (2010) BSR and BHPR guidelines for the management of giant cell arteritis. *Rheumatology*.
23. Dasgupta B (2010) Giant Cell Arteritis Guideline Development Group Concise guidance: diagnosis and management of giant cell arteritis. *Clin Med (Lond)* 10: 381-386.
24. Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, et al. (2004) Tissue production of pro-inflammatory cytokines (IL-1 β , TNF α and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. *Rheumatology* 43: 294-301.
25. Henderson CF, Seo P (2011) Biologic agents in systemic vasculitis. *Int J Clin Rheumatol* 6: 453-462.
26. Guida A, Tufano A, Perna P, Moscato P, De Donato MT, et al. (2014) The thromboembolic risk in giant cell arteritis: a critical review of the literature. *Int J Rheumatol* 2014: 806402.
27. Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM (2007) Treatment of refractory temporal arteritis with adalimumab. *Clin Rheumatol* 26: 1353-1355.
28. Airo P, Antonioli C, Vianelli M, Toniati P (2002) Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. *Rheumatology* 41: 347-9.
29. Osman M, Pagnoux C, Dryden DM, Storie D, Yacyshyn E (2014) The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. *PLoS One* 9: e115026.
30. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, et al. (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. *Ann Int Med* 146: 621-30.
31. Martinez-Taboada V, Rodríguez-Valverde V, Carreño L, Lopez-Longo J, Figueroa M, et al. (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. *Ann Rheumat Dis* 67: 625-30.
32. Seror R, Baron G, Hachulla E, Debandt M, Larroche C, et al. (2014) Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. *Ann Rheumat Dis* 73: 2074-81.
33. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet's disease. *N Engl J Med* 341: 1284-1291.
34. Yurdakul S, Mat C, Tüzün Y, Ozyazgan Y, Hamuryudan V, et al. (2001) A double-blind trial of colchicine in Behçet's syndrome. *Arthritis Rheum* 44: 2686-2692.
35. Saenz A, Ausejo M, Shea B, Wells G, Welch V, et al. (2000) Pharmacotherapy for Behcet's syndrome. *Cochrane Database Syst Rev* : CD001084.
36. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, et al. (2007) Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. *Rheumatology (Oxford)* 46: 736-741.
37. Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. *Semin Arthritis Rheum* 41: 61-70.
38. Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, et al. (2014) Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study. *Ophthalmology* 121: 1877-1884.
39. Lee KM, Jeon YT, Cho JY, Lee CK, Koo JS, et al. (2013) Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. *J Gastroenterol Hepatol* 28: 1829-33.
40. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, et al. (2005) Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. *J Rheumatol* 32: 98-105.
41. Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Behçet disease. *Ocul Immunol Inflamm* 18: 226-232.
42. Olivieri I, Leccese P, D'angelo S, Padula A, Nigro A, et al. (2010) Efficacy of adalimumab in patients with Behcet's disease unsuccessfully treated with infliximab. *Clin Exp Rheumatol* 29: 54-57.
43. Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, et al. (2012) Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. *Biologics* 6: 5-12.
44. Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L (2002) Cryoglobulinemia vasculitis. *Curr Opin Rheumatol* 14: 29-35.
45. Goglin S, Chung SA (2016) Current Treatment of Cryoglobulinemic Vasculitis. *Curr Treat Options Rheumatol* 2: 213-224.
46. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, et al. (2012) A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. *Arthritis Rheum* 64: 843-853.
47. Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR (2005) Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. *Nephrol Dial Transplant* 20: 213-216.
48. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, et al. (2002) Efficacy of the anti-TNF- α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. *Rheumatology* 41:1126-1132.
49. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, et al. (2002) Efficacy of the anti-TNF- α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. *Rheumatology* 41: 1126-32.
50. Rowley AH, Shulman ST (2010) Pathogenesis and management of Kawasaki disease. *Expert Rev Anti Infect Ther* 8: 197-203.
51. Jamieson N, Singh-Grewal D (2013) Kawasaki Disease: A Clinician's Update. *Int J Pediatr* 7.
52. Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, et al. (2014) Management of Kawasaki disease. *Arch Dis Child* 99: 74-83.
53. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, et al. (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. *J Pediatr* 153: 833-838.

54. Brogan RJ, Eleftheriou D, Gnanapragasam J, Klein NJ, Brogan PA (2009) Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. *Pediatr Rheumatol Online J* 7: 3.
55. Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, et al. (2014) Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. *Lancet*. 17: 383
56. Choueiter NF, Olson AK, Shen DD, Portman MA (2010) Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. *J Pediatr* 157: 960-966.
57. Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, et al. (2012) Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. *J Rheumat* 39: 864-867.
58. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS (2004) Infliximab as a novel therapy for refractory Kawasaki disease. *J Rheumatol* 31: 808-810.
59. Song MS, Lee SB, Sohn S, Oh JH, Yoon KL, et al. (2010) Infliximab treatment for refractory Kawasaki disease in Korean children. *Korean Circ J* 40: 334-338.
60. Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. (2011) Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. *J Pediatr* 158: 644-649.
61. Burns J, Song Y, Bujold M, Shimizu C, Kanegaye J, et al. (2013) Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. *Clin Exp Immunol* 174: 337-344.
62. Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, et al. (2014) Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. *Lancet* 383: 1731-1738.
63. Youn Y, Kim J, Hong YM, Sohn S (2016) Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. *Pediatr Infect Dis J* 35: 457-459.
64. Kussmaul A, Maier R (1866) Ueber eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarthritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. *Dtsch Arch Klin Med* 1: 484-518.
65. Feinstein J, Arroyo R (2005) Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. *J Clin Rheumatol* 11: 219-222.
66. Capuozzo M, Ottaiano A, Nava E, Cascone S, Fico R, et al. (2014) Etanercept induces remission of polyarteritis nodosa: a case report. *Front Pharmacol* 5: 122.
67. Zoshima T, Matsumura M, Suzuki Y, Kakuchi Y, Mizushima I, et al. (2013) A case of refractory cutaneous polyarteritis nodosa in a patient with hepatitis B carrier status successfully treated with tumor necrosis factor alpha blockade. *Mod Rheumatol* 23: 1029-1033.
68. Al-Bishri J, le Riche N, Pope JE (2005) Refractory polyarteritis nodosa successfully treated with infliximab. *J Rheumatol* 32: 1371-1373.
69. Watanabe K, Rajderkar DA, Modica RF (2016) A Case of Polyarteritis Nodosa Associated with Vertebral Artery Vasculitis Treated Successfully with Tocilizumab and Cyclophosphamide. *Case Rep Pediatr* 7987081.
70. Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, et al. (2009) Biologic therapy in primary systemic vasculitis of the young. *Rheumatology* 48: 978-986.
71. Seri Y, Shoda H, Hanata N, Nagafuchi Y, Sumitomo S, et al. (2015) A case of refractory polyarteritis nodosa successfully treated with rituximab. *Mod Rheumatol* 12: 1-3.
72. Morgan MD, Drayson MT, Savage COS, Harper L (2011) Addition of Infliximab to Standard Therapy for ANCA-Associated Vasculitis. *Nephron Clin Pract* 117: c89-c97.
73. Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G (2006) Henoch-Schonlein purpura after etanercept therapy for psoriasis. *J Clin Rheumat* 12: 249-251.